electroCore Announces Third Quarter 2021 Financial Results
04 nov. 2021 16h01 HE
|
electroCore, Inc.
Third quarter 2021 revenue grew 17% sequentially and 38% over third quarter 2020 Company to host a conference call and webcast today, November 4, 2021 at 4:30 pm ET ROCKAWAY, N.J., Nov. 04, 2021 ...
Singer-Songwriter Living With Migraine to Perform Song, "Not All in our Heads"
15 sept. 2021 15h39 HE
|
National Headache Foundation
Chicago, IL, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Country music singer-songwriter Allie Sealey will perform at the National Headache Foundation (NHF) gala on Oct. 2 at the Langham Hotel in Chicago,...
Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-07 for the Acute Treatment of Migraine
14 sept. 2021 07h00 HE
|
Axsome Therapeutics, Inc.
NEW YORK, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS)...
Shades for Migraine Partners with Rising Influencers to Empower People with Migraine
25 mai 2021 09h03 HE
|
Association of Migraine Disorders
Rhode Island, May 25, 2021 (GLOBE NEWSWIRE) -- Providence, R.I. (May 25, 2021) – Global awareness campaign, Shades for Migraine®, teams up with two rising social media influencers, YouTuber,...
Trevena, Inc. to Participate at the Sachs Associates 4th Annual Neuroscience Innovation Forum
29 avr. 2021 07h00 HE
|
Trevena Inc.
CHESTERBROOK, Pa., April 29, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central...
Aculief Reviews – Does this Migraine Relief Clip work? – Product Review by Mike Vaughn
24 janv. 2021 23h57 HE
|
Mike Vaughn
New York, Jan. 24, 2021 (GLOBE NEWSWIRE) -- Lifestyle changes and styles, like working and using screens for long periods of time, have brought about migraines and headaches. Headaches can be such a...
Axsome Therapeutics Announces Positive Efficacy and Safety Results from the Phase 3 MOVEMENT Long-Term Trial of AXS-07 in the Acute Treatment of Migraine
31 déc. 2020 06h00 HE
|
Axsome Therapeutics, Inc.
Over 21,000 migraine attacks treated with AXS-07 Achieved migraine pain relief in approximately 70% of patients, and pain freedom in approximately 40% of patients, at 2 hours Achieved...
Cerecin Enrolls First Patient in a Phase 2 Pilot Clinical Trial of Tricaprilin for Migraine Prevention (the Relief Study)
17 déc. 2020 07h40 HE
|
Cerecin
Colorado, USA and Melbourne, Australia, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Cerecin, a biopharmaceutical company focused on brain therapeutics, announced the enrollment of the first patient in its...
Axsome Therapeutics and Veeva Systems Partner to Build Axsome’s Digital-Centric Commercialization™ Platform
04 nov. 2020 07h03 HE
|
Axsome Therapeutics, Inc.
Collaboration provides Axsome access to new digital technologies developed by Veeva NEW YORK and PLEASANTON, Calif., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a...
Axsome Therapeutics Presents New Data from MOMENTUM Phase 3 Trial with AXS-07 Demonstrating Rapid Onset of Action and Reduced Symptom Recurrence in the Acute Treatment of Migraine
24 sept. 2020 06h00 HE
|
Axsome Therapeutics, Inc.
Significantly faster time to pain relief as compared to rizatriptan (p<0.001) Significantly less relapse of migraine pain as compared to rizatriptan (p=0.001) Benefits demonstrated in...